

**Reporting requirement according to paragraph 33 of the 'REACH' regulation
(EG No. 1907/2006)**

May 20, 2009

Dear Sir or Madam,

B. Braun Avitum confirms with the CE-labelling and with the declaration of conformity of our medical devices that the respective products are in compliance with the "essential requirements" of the European Medical Device Directive (93/42/EEC) dated June 14th, 1993.

This includes that B. Braun Avitum medical devices are designed and manufactured in a way that, when used under the conditions and for the purpose intended, they will not compromise the clinical condition or the safety of patients nor the safety and health of users or third parties. This assessment was carried out as part of the B. Braun Avitum Risk Management System implemented according to ISO 14971, "Application of Risk Management to Medical Devices".


Since adoption of the European Regulation 'REACH' (Registration, Evaluation and Authorisation of Chemicals) we now have to inform which devices include a substance named in the so-called list of candidates in a concentration of more than 0.1 mass percentage. This list was announced to the public on the 'ECHA' website (European Chemical Agency) on October 28th, 2008.

According to our files the following product groups of the B. Braun Avitum Division contain more than 0.1 mass percentage DEHP (Bis(2-ethylhexyl)phthalate):


- Bloodline systems for haemodialysis machines, for the acute dialysis machine Diapact CRRT and the H.E.L.P. system
- Fistula needles
- Haemodialysis concentrates and rinsing/priming solutions contained in PVC bags (not applicable to all concentrates and solutions in containers other than PVC bags).

Yours sincerely,

B. Braun Avitum AG



Dr. rer. nat. Wolfgang Feller
Head of B. Braun Avitum Division

i. V. 
Bertram König
Vice President Operations & Quality